

# Replication of hepatitis C virus

Ralf Bartenschlager and Volker Lohmann

Institute for Virology, Johannes-Gutenberg University Mainz, Obere Zahlbacher Straße 67, 55131 Mainz, Germany

## Introduction

After the development of diagnostic tests for hepatitis A and hepatitis B viruses in the 1970s, an additional parenterally transmitted agent responsible for the majority of transfusion-associated non-A, non-B hepatitis cases was recognized. The identification of this agent turned out to be very difficult and only with the advent of recombinant DNA technology was it possible to clone the genome of the virus that was termed hepatitis C virus (HCV) (Choo *et al.*, 1989). Since then HCV has become a focus of intensive research for several reasons (Lavanchy *et al.*, 1999). First, most infections persist, leading in about 50% of all cases to chronic hepatitis, which can develop into chronic active hepatitis, liver cirrhosis and hepatocellular carcinoma. Second, HCV is distributed worldwide, with the number of infected individuals being estimated to be ~ 170 million. Third, the only therapy currently available is combination treatment with a high dose of interferon- $\alpha$  (IFN- $\alpha$ ) and the nucleoside analogue ribavirin. However, only ~ 40% of all patients benefit from this treatment and develop a sustained response, demonstrating the urgent need for more effective antiviral therapeutics.

## HCV genome organization

HCV has been classified as the sole member of a distinct genus called hepacivirus in the family *Flaviviridae*, which includes the flaviviruses, the animal pathogenic pestiviruses and, although this awaits official confirmation, the recently cloned GB virus A (GBV-A), GBV-B and GBV-C/hepatitis G viruses (Murphy *et al.*, 1995). These viruses have in common an enveloped particle harbouring a plus-strand RNA that, in the case of HCV, has a length of ~ 9600 nucleotides. The genome carries a single long open reading frame (ORF) encoding a polyprotein that is proteolytically cleaved into a set of distinct products (Fig. 1). Translation of the HCV ORF is directed via a ~ 340 nucleotide long 5' non-translated region (NTR) functioning as an internal ribosome entry site (IRES) and permitting the direct binding of ribosomes in close proximity to the start codon of the ORF (Tsukiyama-Kohara *et al.*, 1992; Wang *et al.*, 1993). The first ~ 40 nucleotides of the RNA genome are not required for translation but, based on

analogy with other plus-strand RNA viruses, are involved most likely in RNA replication (Boyer & Haenni, 1994). The 3' NTR was only recently discovered (Kolykhalov *et al.*, 1996; Tanaka *et al.*, 1995, 1996; Yamada *et al.*, 1996). It has a tripartite structure composed of a variable sequence following the stop codon of the ORF, a poly(U) tract of heterogeneous length and a highly conserved 98 nucleotide sequence essential for replication *in vivo* (Yanagi *et al.*, 1999; Kolykhalov *et al.*, 2000).

The HCV polyprotein is cleaved co- and post-translationally by cellular and viral proteinases into ten different products, with the structural proteins located in the amino-terminal one-third and the nonstructural replicative proteins in the remainder (Fig. 1) (for recent reviews see Bartenschlager, 1999; Reed & Rice, 1998). The first cleavage product of the polyprotein is the highly basic core protein, forming the major constituent of the nucleocapsid (Yasui *et al.*, 1998). In addition, a number of other functions like modulation of several cellular processes or induction of hepatocellular carcinoma in transgenic mice have been described (Chang *et al.*, 1998; Chen *et al.*, 1997; Matsumoto *et al.*, 1997; Moriya *et al.*, 1998). Envelope proteins (E1 and E2) are highly glycosylated type 1 transmembrane proteins, forming two types of stable heterodimeric complexes: a disulfide-linked form representing misfolded aggregates and a non-covalently linked heterodimer corresponding most likely to the pre-budding complex (Deleersnyder *et al.*, 1997). In addition, E2 was shown to interact with the IFN-induced double-stranded RNA-activated protein kinase PKR. Upon induction by IFN- $\alpha$ , this enzyme reduces protein synthesis via phosphorylation of translation initiation factor eIF2- $\alpha$ , but in cells containing E2, PKR is inhibited, allowing continuation of translation in the presence of IFN (Taylor *et al.*, 1999). Protein p7, located at the carboxy terminus of E2, is a highly hydrophobic polypeptide of unknown function. Most of the nonstructural (NS) proteins 2–5B (the term indicates that these proteins are not expected to be constituents of the virus particle) are required for replication of the viral RNA (Lohmann *et al.*, 1999b). NS2 and the amino-terminal domain of NS3 constitute the NS2–3 proteinase, catalysing cleavage at the NS2/3 site (Grakoui *et al.*, 1993a; Hijikata *et al.*, 1993a; Hirowatari *et al.*, 1993). NS3 is a bifunctional molecule carrying, in the amino-terminal ~ 180 residues, a serine-type proteinase responsible for cleavage at the NS3/4A, NS4A/B, NS4B/5A and NS5A/B sites and, in the carboxy-terminal remainder, NTPase/helicase activities

**Author for correspondence:** Ralf Bartenschlager.  
Fax +49 6131 393 5604. e-mail bartnsch@mail.uni-mainz.de




Fig. 1. HCV genome organization and polyprotein cleavage products. A schematic representation of the HCV genome indicating the positions of the structural and the nonstructural proteins within the polyprotein as well as the 5' and 3' NTRs (thick lines). The polyprotein cleavage products are drawn below. Cleavage sites for host cell signalases (↯), the NS2–3 proteinase (↑), the NS3 proteinase (↓) and an unknown cellular proteinase (↓) are marked.

essential for translation and replication of the HCV genome (Bartenschlager *et al.*, 1993; Eckart *et al.*, 1993; Grakoui *et al.*, 1993b; Gwack *et al.*, 1996; Hong *et al.*, 1996; Kim *et al.*, 1995; Suzich *et al.*, 1993; Tai *et al.*, 1996; Tomei *et al.*, 1993; Kolykhalov *et al.*, 2000). In addition, NS3 may have other properties involved in interference with host cell functions like inhibition of protein kinase A-mediated signal transduction or cell transformation (Borowski *et al.*, 1996; Sakamuro *et al.*, 1995). NS4A is an essential cofactor of the NS3 proteinase and is required for efficient polyprotein processing (Bartenschlager *et al.*, 1994; Failla *et al.*, 1994; Lin *et al.*, 1994b; Tanji *et al.*, 1995a). The function of the hydrophobic NS4B is so far unknown. NS5A is a highly phosphorylated protein and, at least with some HCV isolates, the level of phosphorylation is influenced by NS4A via direct interaction with NS5A or it requires the expression of NS5A in the context of a NS3–5A polyprotein (Asabe *et al.*, 1997; Kaneko *et al.*, 1994; Koch & Bartenschlager, 1999; Neddermann *et al.*, 1999; Tanji *et al.*, 1995b). NS5A phosphorylation is mediated by an as yet unknown cellular kinase (Ide *et al.*, 1997; Reed *et al.*, 1997; Tanji *et al.*, 1995b). For the HCV-H isolate the major phosphorylation site has been mapped to serine residue 2321 of the polyprotein and the proline-rich nature of the flanking sequence suggests that a proline-directed kinase is responsible for NS5A phosphorylation (Reed & Rice, 1999). The role NS5A may play in RNA replication is so far not known, but based on analogy with other RNA viruses, where phosphoproteins are important regulators of replication, one could assume that NS5A plays a similar role. Apart from such a function, NS5A appears to be involved in resistance of the infected cell to the antiviral effect of IFN. At least for some HCV isolates NS5A is able to bind to PKR, blocking the translational reduction in the IFN-treated cell (Gale *et al.*, 1997, 1998). Interestingly, an alanine substitution for the major phosphorylation site at serine residue 2321 did not affect the NS5A:PKR interaction, showing that phosphorylation at this particular site is not required for complex formation with PKR (Reed & Rice, 1999). NS5B was identified as the RNA-dependent RNA polymerase (RdRp) (Al *et al.*, 1998; Behrens *et al.*, 1996; Lohmann *et al.*, 1997; Yamashita *et al.*, 1998; Yuan *et al.*, 1997).

## Virus replication

HCV nonstructural proteins and viral RNA have been detected in livers of infected patients or experimentally inoculated chimpanzees, confirming that the liver is a site of HCV replication (for a review see Blight & Gowans, 1995). Unfortunately, the amounts of viral proteins and RNA in infected tissues are very low, necessitating the use of highly sensitive but also less reliable detection methods. This may in part explain why the reported number of HCV-positive cells detected in infected liver tissue is contradictory and estimates vary between less than 5% and up to 100% (Blight & Gowans, 1995). Apart from liver cells, there is strong evidence that HCV can also replicate in peripheral blood mononuclear cells (PBMCs) both *in vivo* and *ex vivo* or in experimentally infected B- and T-cell lines (see below). Such a lymphotropism may account for the numerous immunological disorders, in particular type II and type III cryoglobulinaemia, observed in more than 50% of chronic hepatitis C patients (Esteban *et al.*, 1998).

The dynamics of HCV replication can be deduced from the rapid rates of virus production and emergence of mutants. A careful analysis of viral dynamics during antiviral treatment of patients with IFN- $\alpha$  revealed a virion half-life of 3–5 h and a clearance and production rate of  $\sim 10^{12}$  particles per day (Zeuzem *et al.*, 1998; Neumann *et al.*, 1998; Ramratnam *et al.*, 1999). Although in absolute amounts these numbers are high, they are not with respect to a single cell. Assuming that  $\sim 10\%$  of the hepatocytes of a liver are infected and that a liver contains  $\sim 2 \times 10^{11}$  hepatocytes, this would correspond to a virion production rate of 50 particles per hepatocyte per day (Neumann *et al.*, 1998).

Another feature of HCV replication is the rapid generation of virus variants. In fact, based on the genomic variability in a small region of NS5B, HCV has been classified into at least six genotypes each with several subtypes (Simmonds *et al.*, 1993). Even within a patient HCV does not exist as a single entity but rather as a swarm of microvariants of a predominant 'master sequence', a phenomenon that has been referred to as quasispecies (for a review see Holland *et al.*, 1992). The production of such a large number of variants is primarily due




Fig. 2. Hypothetical model of the HCV replication cycle. Upon infection of the host cell (large rectangle) the plus-strand RNA genome (+ RNA) is liberated into the cytoplasm and translated. The polyprotein is processed and viral proteins remain tightly associated with membranes of the ER. Minus-strand RNA (-RNA) is synthesized by the replicase composed of NS3-5B and serves as template for production of excess amounts of plus strand. Via interaction with the structural proteins plus-strand RNA is encapsidated. Particles are enveloped by budding into the lumen of the ER and virus particles are exported via transit through the Golgi complex.

to the high error rate of the viral RdRp that, based on analogies with RdRps of other plus-strand RNA viruses, is expected to be in the range of  $10^{-4}$ . This high error rate is reflected by the high mutation rate observed in patients or experimentally inoculated chimpanzees. Using comparative sequence analyses of HCV genomes isolated over intervals of 8 or 13 years a mutation rate of  $1.44 \times 10^{-3}$  or  $1.92 \times 10^{-3}$  base substitutions per site per year was found, respectively (Ogata *et al.*, 1991; Okamoto *et al.*, 1992). The high variation observed with HCV replication may also account for the fact that a significant fraction of virus genomes appear to be defective (Martell *et al.*, 1992).

Owing to the lack of a convenient animal model and an efficient cell culture system our current understanding of the molecular mechanisms of HCV replication is based primarily on analogies to the closely related flavi- and pestiviruses and on the characterization of recombinant HCV proteins. Using this limited information the HCV replication cycle can be summarized as follows (Fig. 2): (1) penetration of the host cell and liberation of the genomic RNA from the virus particle into the cytoplasm; (2) translation of the input RNA, processing of the polyprotein and formation of a replicase complex associated with intracellular membranes; (3) utilization of the input plus-strand for synthesis of a minus-strand RNA intermedi-

ate; (4) production of new plus-strand RNA molecules which in turn can be used for synthesis of new minus strands, for polyprotein expression or packaging into progeny virions; (5) release of virus from the infected cell.

#### Attachment and entry

The first step in a virus life-cycle is the attachment of the infectious particle to the host cell, for which a specific interaction between a receptor on the cell surface and a viral attachment protein on the surface of the particle is required. Recently, CD81 was identified as a putative HCV receptor based on its strong interaction with E2 as well as with virus particles *in vitro* (Pileri *et al.*, 1998). Furthermore, preincubation of the HCV-containing plasma used for the binding studies with sera from chimpanzees that were protected from HCV challenge by vaccination with recombinant E1 and E2 also blocked *in vitro* binding of HCV to CD81 (Pileri *et al.*, 1998). However, whether virus binding to CD81 is followed by internalization of the virus particle is not known.

Apart from this route, HCV as well as other members of the *Flaviviridae* family may enter the cell by binding to low-density lipoprotein (LDL) receptors. Based on the observation that HCV particles are associated with beta-lipoproteins (Thomssen *et al.*, 1992), Agnello *et al.* (1999) analysed whether endo-

cytosis of HCV is mediated by LDL receptors. Using *in situ* hybridization to determine HCV-RNA-positive cells, a direct correlation between the level of cell surface-expressed LDL receptor and the number of positive cells was found. This result and the finding that HCV does not bind to COS-7 cells unless they have been transfected with the LDL receptor gene (Monazahian *et al.*, 1999) suggest that HCV particles associated with LDL bind to this receptor. Whether interaction with the LDL receptor or CD81 leads to a productive infection remains to be determined.

While the nature of the HCV receptor is not known currently, the major envelope glycoprotein E2 is thought to be responsible for initiating virus attachment to the host cell because E2-specific antisera can block binding to cells (Rosa *et al.*, 1996; Zibert *et al.*, 1995; Farci *et al.*, 1996). The role of E1 is less clear but the presence of a stretch of hydrophobic amino acids tentatively called the E1 fusion peptide, displaying similarities to the fusion peptides of paramyxovirus and flavivirus suggests that E1 is involved in membrane fusion (Flint *et al.*, 1999). To study the early steps in the HCV life-cycle, Lagging *et al.* (1998) generated vesicular stomatitis virus (VSV) pseudotypes. They expressed chimeric envelope proteins composed of the HCV E1 or E2 ectodomains fused to the transmembrane and cytoplasmic domains of the VSV G protein. As indicated by the formation of plaques, a baby hamster kidney cell line (BHK-21), the human T-cell line MOLT4 and the human hepatoma cell line HepG2 were susceptible to infection with the pseudotypes, but the human cervical carcinoma cell line HeLa and the human embryonic lung cell line L-132 were not. However, only pseudotypes carrying either the E1 or the E2 ectodomain were used, not pseudotypes with both chimeric HCV proteins. This is surprising, because E2 acts as a chaperone for E1, which in the absence of E2 forms misfolded aggregates (Michalak *et al.*, 1997). Furthermore, E1 and E2 form stable heterodimers that most likely represent the native form found in the HCV envelope (Dubuisson *et al.*, 1994). Finally, studies with engineered cell surface-expressed E2 glycoproteins folded in a manner comparable to authentic E2 demonstrated that this protein alone did not enable cell fusion (Flint *et al.*, 1999).

### Polyprotein translation and processing

Once inside the cytoplasm the genomic RNA is directly translated. Since HCV most likely does not encode a methyltransferase activity and replicates in the cytoplasm where such cellular enzymes are missing, the genome is not capped. Therefore, translation of the viral RNA is not mediated by a cap-dependent mechanism with ribosomes scanning along the RNA up to the first initiator AUG codon (depending on the isolate there are 4–5 start codons upstream of the polyprotein translation start site), but rather by an IRES (Tsukiyama-Kohara *et al.*, 1992; Wang *et al.*, 1993). This RNA element residing approximately between nucleotides 40 and 355 forms four

highly structured domains. With the exception of one report (Fukushi *et al.*, 1994) the small domain I, forming a single stem-loop between nucleotides 5 and 20, was shown to be dispensable for translation activity and the 5' border of the IRES was mapped between nucleotides 38 and 46 (Honda *et al.*, 1996; Rijnbrand *et al.*, 1995; Yoo *et al.*, 1992). The fact that deletion of the region encompassing domain I stimulates translation suggests a regulatory role of this sequence for polyprotein translation. Because of its 5' proximal position it may also be involved in RNA replication. Two oligopyrimidine tracts are present in the IRES, one in the apical loop of domain III and one between domain III and the small domain II. Domain IV consists of a small stem-loop containing the polyprotein start codon at nucleotide position 342 and forms a pseudoknot via base-pairing with a loop in domain III. Since mutagenesis or insertion of AUG initiator codons upstream from the polyprotein start codon have little effect on IRES activity, ribosomes appear to bind in close proximity to the polyprotein initiator AUG with little or no scanning (Reynolds *et al.*, 1996; Rijnbrand *et al.*, 1996). The mapping of the actual border of the 3' end of the IRES is still a matter of debate. Most experimental evidence suggests that sequences of the core coding sequence, but not the core protein itself, are required for full IRES activity (Honda *et al.*, 1996; Reynolds *et al.*, 1995; Zhao *et al.*, 1999). However, whether the core-coding sequence is a real component of the IRES or is required to prevent unfavourable base-pairings of the IRES with downstream sequences, disturbing the structure of the 5' NTR, is not known. In agreement with the latter assumption purified 40S ribosome subunits were found to bind to an IRES lacking core-coding sequences (Pestova *et al.*, 1998). In the same report it was also shown that the HCV IRES binds specifically to the 40S ribosome subunit and does not require any additional translation factors. This property is unique among all eukaryotic RNAs and resembles the interaction of the prokaryotic 30S ribosome subunit with the Shine–Dalgarno sequence (Pestova *et al.*, 1998). The IRES elements of picornaviruses require additional cellular factors for binding of the 40S ribosome subunit.

Activity of the HCV IRES is influenced by several factors. First, the X-tail at the very 3' end of the HCV genome appears to enhance IRES-dependent translation by an as yet unidentified mechanism (Ito *et al.*, 1998). Second, several cellular factors have been demonstrated to bind to the HCV IRES and, in most cases, stimulate translation. These include polypyrimidine-tract-binding protein (PTB) (Ali & Siddiqui, 1995; Kaminski *et al.*, 1995), the La antigen (Ali & Siddiqui, 1997), heterogeneous nuclear ribonucleoprotein L (Hahn *et al.*, 1998) and as yet unidentified proteins with apparent molecular masses of 120, 87 and 25 kDa (Fukushi *et al.*, 1997; Yen *et al.*, 1995). The requirements for cellular factors for IRES activity may also explain the dependence on the cell cycle. Using cell lines stably expressing bicistronic reporter constructs with a cap-dependently expressed upstream reporter and a down-



stream reporter translated from the HCV IRES it was found that IRES-dependent translation was greatest in mitotic and lowest in quiescent ( $G_0$ ) cells (Honda *et al.*, 2000). One possible explanation would be that HCV translation is regulated by cellular proteins that vary in abundance or activity during the cell cycle.

Directed by the IRES, the polyprotein is translated at the rough endoplasmic reticulum (ER) and cleaved co- and post-translationally by host cell signalases and two viral proteinases. In the last few years a wealth of information regarding the mechanisms of polyprotein processing has been published. It is beyond the scope of this review to summarize all of them and the interested reader is referred to recently published reviews (Bartenschlager, 1999; De Francesco *et al.*, 1998; Reed & Rice, 1998). As deduced from hydrophobic sequences preceding the cleavage sites and the dependence on microsomal membranes, the C-NS2 region is processed by host signal peptidases cleaving at the C/E1, E1/E2, E2/p7, p7/NS2 junctions (Fig. 1) (Grakoui *et al.*, 1993*b*; Hijikata *et al.*, 1991; Lin *et al.*, 1994*a*; Mizushima *et al.*, 1994). The production of processing intermediates, most notably an E2-p7-NS2 protein, indicates that not all cleavages within the structural region are cotranslational. Furthermore, a second post-translational cleavage close to the carboxy terminus of the core protein takes place, removing the E1 signal sequence by an as yet unidentified cellular enzyme (Santolini *et al.*, 1994; Hüsey *et al.*, 1996). Processing between NS2 and NS3 is a rapid intramolecular reaction and is accomplished by the NS2-3 proteinase (Grakoui *et al.*, 1993*a*; Hijikata *et al.*, 1993*a*; Santolini *et al.*, 1995). Efficient cleavage at this site requires the 130 carboxy-terminal residues of NS2 and the first 180 amino acids of NS3. Within the NS2 sequence His-952 and Cys-993 are essential for enzymatic activity (Grakoui *et al.*, 1993*a*; Hijikata *et al.*, 1993*a*) and it has been proposed that NS2-3 is a cysteine proteinase with His-952 and Cys-993 forming a catalytic dyad or, together with Glu-972, a catalytic triad (Gorbalenya & Snijder, 1998). Alternatively, owing to the activation by zinc and the inhibition by chelating agents like EDTA, the NS2-3 proteinase might be a zinc-dependent metalloproteinase (Hijikata *et al.*, 1993*a*). However, since zinc is required for proper folding of the NS3 proteinase domain it is not known whether zinc is bound by the NS2 domain too or whether the activating effect is due to proper folding of the NS3 domain. Alternatively, the zinc bound by the NS3 domain might play an essential role in catalysis (Wu *et al.*, 1998).

Processing of the NS3-5B region is mediated by the NS3 proteinase with the following preferred but not obligatory order of cleavages: NS3/4A  $\rightarrow$  NS5A/B  $\rightarrow$  NS4A/B  $\rightarrow$  NS4B/5A (Bartenschlager *et al.*, 1994; Failla *et al.*, 1995; Lin *et al.*, 1994*b*; Tanji *et al.*, 1994). Processing at the NS3/4A site is a cotranslational intramolecular reaction whereas cleavage at the other sites can be mediated intermolecularly. However, the HCV proteins most likely form a stable higher-order complex associated with intracellular membranes (Hijikata *et al.*,

1993*b*; Ishido *et al.*, 1998; Koch & Bartenschlager, 1999; Lin *et al.*, 1997; Neddermann *et al.*, 1999). Therefore, even after liberation of NS3 from the polyprotein, the enzyme and its substrate are in very close proximity.

Although enzymatically active on its own, proteolytic activity of NS3 is greatly stimulated by NS4A both in transfected cells and in various *in vitro* assay systems. Coprecipitation studies demonstrated the formation of a detergent-stable complex and the interaction domains have been mapped to the  $\sim$  30 amino-terminal residues of NS3 and a 12 residue sequence in the centre of NS4A (Bartenschlager *et al.*, 1995; Failla *et al.*, 1995; Lin *et al.*, 1994*b*, 1995; Satoh *et al.*, 1995; Tanji *et al.*, 1995*a*), which can be supplied as a synthetic peptide without loss of activation function (Butkiewicz *et al.*, 1996; Koch *et al.*, 1996; Shimizu *et al.*, 1996*a*; Steinkühler *et al.*, 1996; Tomei *et al.*, 1996). Since mutational ablation of complex formation drastically reduces proteinase activity, it was assumed that interaction of NS4A with NS3 induces conformational changes within the proteinase domain, enhancing enzymatic activity. This hypothesis was confirmed by the resolution of the three-dimensional X-ray structure of the NS3 proteinase (Love *et al.*, 1996) or NS3 complexed with a synthetic NS4A peptide (Kim *et al.*, 1996; Yan *et al.*, 1998). Overall, the enzyme adopts a chymotrypsin-like fold and consists of two  $\beta$ -barrel domains separated by a deep cleft where the amino acid residues forming the catalytic triad are located. The carboxy-terminal domain forms a six-stranded  $\beta$ -barrel and its structural integrity requires a tetrahedrally coordinated zinc ion (De Francesco *et al.*, 1996*b*; Stempniak *et al.*, 1997). In the absence of NS4A the  $\sim$  30 amino-terminal NS3 residues are flexible and extend away from the protein, whereas in the presence of the cofactor, this region is highly structured and participates in an eight-stranded  $\beta$ -barrel with one strand contributed by NS4A tightly intercalated via several side chains into the NS3 domain. A second structural rearrangement upon NS4A binding leads to an optimization of the geometry of the catalytic triad, accounting most likely for the enhancement of proteinase activity (Love *et al.*, 1998; Yan *et al.*, 1998). In addition to serving as a proteinase cofactor, NS4A has two further functions that might contribute to efficient polyprotein cleavage and replication. First, increasing the metabolic stability of NS3 that in the absence of NS4A is degraded very rapidly, and second, anchoring NS3 to intracellular membranes where most of the HCV proteins are located, thereby increasing the local enzyme:substrate concentration and facilitating the formation of a membrane-associated replicase complex (Tanji *et al.*, 1995*a*; Wölk *et al.*, 2000).

A feature conserved in many plus-strand RNA virus families is that proteinase and NTPase/helicase activities reside in a single polypeptide, and the same is found with NS3 of HCV. In fact, two lines of evidence suggest an interdomain coupling.

(1) Although the catalytic efficiencies of the isolated proteinase domain and full-length NS3 are very similar this is

not the case with the helicase. A comparison of RNA unwinding activities of a recombinant single chain NS4A–full-length NS3, a full-length NS3 without NS4A and the isolated helicase domain suggests that the presence of the proteinase domain and NS4A enhance helicase activity (Howe *et al.*, 1999). This enhancement may be due to, first, a stabilization of the helicase fold in the full-length complex (Yao *et al.*, 1999) and, second, RNA binding sites in the proteinase domain contributing to helicase substrate binding (Gallinari *et al.*, 1998).

(2) The resolution of the three-dimensional X-ray crystal structure of a single chain fusion protein of full-length NS3 and the NS4A activator domain revealed that the proteinase and the helicase/NTPase domains are segregated and connected by a flexible single strand (Yao *et al.*, 1999). Interestingly, in this molecule the proteinase active site is occupied by the carboxy terminus of NS3. This observation suggests an autoinhibition of the proteinase that may be overcome by interaction with the polyprotein substrate, inducing structural changes and displacing the inhibitor from the active site (Barbato *et al.*, 1999; Yao *et al.*, 1999).

### RNA replication

As deduced from several coprecipitation studies (Hijikata *et al.*, 1993b; Ishido *et al.*, 1998; Lin *et al.*, 1997), most or all of the HCV polyprotein cleavage products, in particular NS3–5B, form a replicase complex associated with intracellular membranes that most likely contains cellular proteins too. The formation of such a complex is a feature typical of plus-strand RNA viruses like poliovirus or flaviviruses (Bolten *et al.*, 1998; Westaway *et al.*, 1997) and it allows the production of viral proteins and RNA in a distinct compartment. In addition, complex formation permits the tight coupling of functions residing in different polypeptide chains.

The individual steps underlying RNA replication are largely unknown. It is obvious that the NS5B RdRp is the key player catalysing the synthesis of minus- and plus-strand RNA. *In vitro* the enzyme prefers a primer-dependent initiation of RNA synthesis, either by elongation of a primer hybridized to an RNA homopolymer or via a 'copy-back' mechanism when using heteropolymeric templates (Al *et al.*, 1998; Behrens *et al.*, 1996; Ferrari *et al.*, 1999; Lohmann *et al.*, 1997; Yamashita *et al.*, 1998; Yuan *et al.*, 1997). In the latter case, sequences at the 3' end fold back intramolecularly and hybridize, generating a 3' end that can be used for elongation, resulting in a product approximately twice the length of the input template. However, at least under certain experimental conditions, HCV NS5B, as well as the RdRp of the closely related pestivirus bovine viral diarrhoea virus (BVDV), can initiate RNA synthesis *de novo* and it is plausible that this mechanism also operates *in vivo* (Kao *et al.*, 1999; Oh *et al.*, 1999; Luo *et al.*, 2000; Zhong *et al.*, 2000). Interestingly, when using high concentrations of GTP or ATP, HCV NS5B can synthesize

RNA primer independently from the homopolymeric templates poly(C) and poly(U), respectively, whereas RNA synthesis from poly(I) or poly(A) templates is primer-dependent irrespective of the NTP concentration (Luo *et al.*, 2000). These results suggest that the enzyme can probably only use GTP or ATP for *de novo* initiation. It is interesting to note that the 5'-terminal nucleotides of plus- or minus-strand RNA are guanosine or adenine, respectively. The dependence of *de novo* initiation on high GTP or ATP concentration and the inability of the enzyme to initiate RNA synthesis from poly(A) templates also explains why some groups only observed primer-dependent RNA synthesis with their *in vitro* assays (Al *et al.*, 1998; De Francesco *et al.*, 1996a; Ferrari *et al.*, 1999; Lohmann *et al.*, 1999a; Yamashita *et al.*, 1998).

A still unresolved question is how template specificity is achieved. In most studies NS5B was found to utilize and bind to virtually every RNA (and even DNA) template, albeit with different efficiencies. However, using electrophoretic mobility shift assays and competition experiments, Cheng *et al.* (1999) provided evidence for a preferential binding of recombinant NS5B to a sequence in the 3' coding region of NS5B. Alternatively, template specificity may be accomplished by the high local concentration of NS5B and the RNA genome from which it is translated, within the replicase complex. A preferential *cis*-activity of NS5B also would discriminate against RNA genomes containing stop codons or frame-shift mutations introduced by errors of the viral replicase, reminiscent of what has been described for poliovirus (Novak & Kirkegaard, 1994). While *in vitro* NS5B is able to copy even a complete full-length HCV genome (Lohmann *et al.*, 1997), it is very likely that *in vivo* additional viral or cellular factors are required. Possible viral candidates are the NS3 helicase, by unwinding stable structures in the RNA template and facilitating replication, or the phosphoprotein NS5A. Although the replication function of this protein could not be studied thus far, by analogy to other RNA viruses it is tempting to speculate that NS5A is involved in regulation of RNA replication. For example, in the case of VSV, RNA synthesis occurs only after phosphorylation of the P protein (Barik & Banerjee, 1992). In the case of the Dengue virus NS5 replicase, subcellular localization and interaction with NS3 are altered by the level of phosphorylation (Kapoor *et al.*, 1995). Phosphorylation of NS5 or NS5A is a biochemical property conserved in all members of the flaviviruses studied thus far, suggesting that this modification plays an important role in the life-cycle of these viruses (Reed *et al.*, 1998).

In addition to viral proteins, cellular components are probably involved in RNA synthesis, too. One candidate is PTB, found to specifically interact with sequences at the 3' NTR (Chung & Kaplan, 1999; Ito & Lai, 1997; Tsuchihara *et al.*, 1997). Another candidate is glyceraldehyde-3-phosphate dehydrogenase, binding to the poly(U)-sequence in the 3' NTR (Petrik *et al.*, 1999). Finally, cellular proteins provisionally called p87 and p130 were identified by UV-cross linking

experiments with the X-tail sequence, but the nature of these proteins remains to be determined (Inoue *et al.*, 1998).

Proteins from other viruses may also affect HCV replication. It is interesting to note that the cell lines supporting HCV replication the best are, in most cases, (co-)infected with other viruses like human T-lymphotropic virus type I (in the case of the MT2 T-cell line), a murine retrovirus (in the case of the MOLT4-Ma T-cell line) or Epstein–Barr (EBV) (in the case of the Daudi B-cell line). Furthermore, Sugawara *et al.* (1999) observed that HCV-positive patients with a hepatocellular carcinoma frequently have a high EBV load, and presented evidence that the enhancement of HCV replication is mediated by EBV nuclear antigen 1. Since this protein is localized in the nucleus, whereas HCV replication occurs in the cytoplasm, the enhancement may be due to an indirect effect, e.g. via activation of transcription of cellular genes, although there is no cellular promoter with an EBV nuclear antigen 1 binding motif known.

### Virion assembly and release

In the absence of systems allowing the production of biochemical amounts of virus particles, the assembly of HCV cannot be studied in detail. One potential approach to overcome this limitation is the production of virus-like particles (VLPs) by expression of the structural proteins in heterologous systems, but for HCV this turned out to be very difficult. Thus far there are two reports describing the formation of VLPs. In one report the full-length HCV coding region was transiently expressed with the vaccinia virus T7 hybrid system in HeLa G cells (Mizuno *et al.*, 1995). Particles with diameters of  $\sim 30$  and 45 nm, assumed to correspond to non-enveloped core-like particles and enveloped particles, respectively, were found. In another report, Baumert *et al.* (1998) used recombinant baculoviruses to express a region of the HCV genome corresponding to a part of the 5' NTR and the C–E2 region in insect cells. They observed VLPs containing selectively encapsidated HCV RNA. Although this report is promising, the efficiency of VLP formation still appears rather low, because the majority of the HCV proteins form aggregates and only a minority assemble to produce VLPs. Furthermore, these particles reside in intracellular membrane vesicles and are not transported out of the cell.

Particle formation may be initiated by core protein interacting with the RNA genome. Although *in vitro* core protein binds to RNA without detectable specificity, recent evidence indicates a preferential intracellular binding to RNA sequences in the 5' half of the HCV genome (Shimoike *et al.*, 1999). Such binding may not only accomplish a selective packaging of the plus-stranded genome but also appears to repress translation from the IRES, suggesting a potential mechanism to switch from translation/replication to assembly (Shimoike *et al.*, 1999). Whether the core protein forms a distinct nucleocapsid structure or a rather non-structured

ribonucleoprotein complex with the RNA genome is not known. Certainly, core protein interacts with itself and the sequences required for this interaction have been mapped to the amino-terminal 115 residues (Matsumoto *et al.*, 1996). Within this region a tryptophan-rich primary interaction domain was identified between residues 82 and 102 that is masked in the full-length core protein and revealed only under certain experimental conditions (Nolandt *et al.*, 1997).

A feature typical of the HCV E proteins is their retention in the ER compartment when expressed with various heterologous systems in cell culture (Dubuisson *et al.*, 1994). The retention is achieved by signals in the transmembrane domains of E1 and E2 and it has been shown to be a true retention in the ER (Duvet *et al.*, 1999; Cocquerel *et al.*, 1999). This observation suggests that viral nucleocapsids acquire their envelope by budding through ER membranes. In this case the virus may be exported via the constitutive secretory pathway. In agreement with this assumption, complex N-linked glycans were found on the surface of partially purified virus particles, suggesting virus transit through the Golgi (Sato *et al.*, 1993). However, since HCV particles tend to associate with cellular components it remains to be determined whether these glycans are present on the E proteins or on cellular proteins associated with HCV particles.

## Model systems to study HCV replication

### HCV-related viruses

As alluded to in a previous section, HCV belongs to the family *Flaviviridae* and is most closely related to pestiviruses and the GB-/hepatitis G viruses. Despite a low sequence identity between the genomes of these viruses and HCV their similar genomic organizations, in particular the superimposable delineation of the nonstructural proteins 2–5B and their functional homologies (proteinase, helicase, RdRp), make these viruses an attractive model. Although for GBV-B, infectious clones have recently been described (Bukh *et al.*, 1999), pestiviruses provide the better model because of both the availability of cloned infectious genomes and efficient cell culture systems (Moormann *et al.*, 1996; Ruggli *et al.*, 1996; Meyers *et al.*, 1996; Mendez *et al.*, 1998). We can expect that the overall replication schemes of HCV and pestiviruses are similar and, therefore, studies performed with pestiviruses should help to clarify the HCV replication cycle. To give one example, it was shown for BVDV that a subgenomic RNA, originally identified as a defective interfering particle and lacking all the structural proteins can replicate autonomously in cells (Behrens *et al.*, 1998). This observation could be confirmed with HCV and led to the construction of RNAs capable of replicating in a human hepatoma cell line (Lohmann *et al.*, 1999b; see below). However, apart from these overall similarities, distinct differences exist. For example, a hallmark of pestiviruses is the formation of cytopathogenic variants

characterized by the formation of NS3 that in the case of non-cytopathogenic isolates is produced as an NS2–3 fusion protein. In the case of all HCV isolates analysed thus far there is no evidence for the formation of such a protein but rather an obligatory cleavage at the NS2/3 junction (see above). Another difference relates to host cell factors required for pestivirus or HCV replication. For example, the BVDV replicon described by Behrens *et al.* (1998) was shown to replicate in several different cell lines of bovine and even human origin, including the human hepatoma cell lines HepG2 and Huh-7. In contrast, the subgenomic HCV replicon developed by Lohmann *et al.* (1999b) thus far only replicates in Huh-7 cells, suggesting a dependence on distinct cellular factors.

### Animal models

The only animal that can be infected with HCV reproducibly is the chimpanzee, but its use is limited by ethical reasons, its scarcity and high maintenance costs. In an attempt to establish a small animal model Xie *et al.* (1998) experimentally inoculated *Tupaia*s (*T. belangeri chinensis*), a species shown to be susceptible to infection with the hepatitis B virus (Walter *et al.*, 1996; Yan *et al.*, 1996). However, only about one-quarter of the animals became infected with HCV and developed either transient or intermittent viraemia with rather low titres. Recently, two potential alternatives have been described for the propagation of hepatitis B viruses that might be used for HCV as well. Both systems are based on the engraftment of human liver tissue into immunocompromised mice. In the so-called trimera system lethally irradiated mice are rescued with SCID mouse bone marrow cells and used as transplant recipients for human liver pieces infected *ex vivo* (Ilan *et al.*, 1999). The other system uses transgenic mice containing the urokinase-type plasminogen activator gene whose expression under control of the liver-specific albumin promoter is hepatotoxic and destroys a high proportion of liver cells. These mice were crossed to mice that due to a recombination activation gene 2 knockout lack mature B and T lymphocytes. Upon transfer of liver cells from an animal susceptible to infection with a hepadnavirus into these mice, the parenchymas of the regenerating mouse livers were composed of up to 90% of the transplanted cells and after infection with the hepadnavirus these mice became highly viraemic (Petersen *et al.*, 1998). Although both mouse systems have thus far only been used for the propagation of hepadnaviruses, the methodologies might be used for HCV as well.

### Infection of cultured cells with HCV

In the last few years several cell culture propagation systems for HCV have been described that are based on the infection of primary cell cultures or cell lines or the cultivation of primary cells from chronically infected patients. However,

thus far these systems suffer from poor reproducibility and a low level of HCV replication that can be measured only with highly sensitive techniques. In many cases the minus-strand RNA intermediate that is only formed upon productive replication was measured by strand-specific RT-PCR, but owing to false priming during the RT-PCR process this assay alone is not really reliable. Several modifications of this method have been developed (Gunji *et al.*, 1994; Lanford *et al.*, 1994), but scepticism remains. Therefore, in addition to minus-strand RNA detection, several other indicators for productive replication have been used, such as an increase of plus-strand RNA during the cultivation period (determined either by b-DNA assay or quantitative RT-PCR), the inhibition of replication upon incubation of the cells with IFN- $\alpha$  or antisense oligonucleotides, the transmission of cell-culture-grown HCV to naive cells, the sequence analysis of HCV genomes or genome fragments to demonstrate genomic variability and selection of variants upon infection and cultivation, the detection of viral antigens by immunofluorescence or flow cytometry and the long-term propagation of HCV. A representative selection of these reports is given in Table 1 and only a few will be described in some detail here.

The infection of primary hepatocytes from humans or chimpanzees with high-titre HCV-containing serum has been described by several groups (Fournier *et al.*, 1998; Iacovacci *et al.*, 1993; Lanford *et al.*, 1994; Rumin *et al.*, 1999). Although discussed controversially (Lanford *et al.*, 1995; Laskus *et al.*, 1997), infection of PBMCs seems possible, too, indicating that HCV can also replicate in extrahepatic cells (Cribier *et al.*, 1995; Lerat *et al.*, 1996). Consistent with this notion, HCV replication was reported in PBMCs isolated from chronically infected patients (Bouffard *et al.*, 1992; Müller *et al.*, 1993; Zignego *et al.*, 1992).

Since primary cell cultures are not routinely available, most attempts have been undertaken with cell lines of human origin. With respect to hepatoma cell lines, the most detailed results are available for the non-neoplastic cell line PH5CH (Ikeda *et al.*, 1998; Kato *et al.*, 1996). Evidence for HCV replication in these cells is based on (1) the detection of HCV RNA up to 100 days post-infection, (2) the loss of plus-strand RNA upon incubation of the infected cells with IFN- $\alpha$ , and (3) a strong selection for HCV variants in the hypervariable region 1 (HVR1) of the E2 protein, suggesting that only certain variants can bind to or replicate in these cells. A similar decrease of complexity of viral quasispecies has been described for HCV propagated in primary human hepatocytes for up to 3 months (Rumin *et al.*, 1999).

T- and B-cells selected for high HCV replication have been derived from the T-cell lines MT-2 and MOLT-4 and the B-cell line Daudi. For example, an MT-2C cell clone was described that supports HCV replication for up to 198 days post-infection (Mizutani *et al.*, 1996b). By comparing the complete sequence of the HCV genome replicating in these cells with the sequences present in the inoculum it was found that only a



**Table 1.** Examples of *in vitro* infection systems for HCV

Cell type*	Detection method†	Time‡	References
Cultivation of infected PHH	(+); (-); IF; HVR sequence; transmission	28	Ito <i>et al.</i> (1996)
Cultivation of infected PBMC	(+); (-); antigen	9	Bouffard <i>et al.</i> (1992); Müller <i>et al.</i> (1993); Zignego <i>et al.</i> (1992)
PHH (foetal)	(+); (-)	24	Iacovacci <i>et al.</i> (1993)
PCH	(+); (-); IFN- $\alpha$	25	Lanford <i>et al.</i> (1994)
PBMC	(+); (-); ISH; transmission	26	Cribier <i>et al.</i> (1995)
PHH	(+); (-)	14	Fournier <i>et al.</i> (1998)
PHH	(+); (-)	90	Rumin <i>et al.</i> (1999)
HepG2; WRL68 hepatocytes	(+); (-)	< 20; 62	Tagawa <i>et al.</i> (1995)
CE B-cell	(+); IF	65	Bertolini <i>et al.</i> (1993)
TOFE B-cell	(+); 5' NTR sequence	~ 180	Valli <i>et al.</i> (1995)
HepG2, Huh-7 hepatocytes and others	(+); (-); transmission	130	Seipp <i>et al.</i> (1997)
PH5CH hepatocytes	(+); HVR sequence	30	Kato <i>et al.</i> (1996)
PH5CH clones	(+); IFN- $\alpha$	100	Ikeda <i>et al.</i> (1998)
MT-2 T-cell	(+); (-); HVR sequence	15	Kato <i>et al.</i> (1995)
MT-2C cell clone	(+); (-); IFN- $\alpha$ ; antisense	30/80	Mizutani <i>et al.</i> (1996b)
MT-2C cell clone	(+); transmission; HVR sequence	198	Mizutani <i>et al.</i> (1996a)
MT-2C cell clone	Complete genome sequence		Sugiyama <i>et al.</i> (1997)
MOLT-4 Ma T-cell	(+); (-); ISH; IF	25	Shimizu <i>et al.</i> (1992)
MOLT-4 Ma T-cell	Transmission		Shimizu & Yoshikura (1994)
HPB-Ma T-cell	(+); (-); IF	76	Shimizu <i>et al.</i> (1993)
HPB-Ma10-2 clone; Daudi B-cell	Genome-sequences; transmission; EM	> 365	Nakajima <i>et al.</i> (1996); Shimizu <i>et al.</i> (1996b)
Daudi B-cell	Infection of chimpanzee		Shimizu <i>et al.</i> (1998)

\* Primary cell culture or cell line used for infection. PHH, Primary human hepatocytes; PCH, primary chimpanzee hepatocytes.

† Method used to monitor HCV replication. (+), Plus-strand RNA; (-), minus-strand RNA; IFN- $\alpha$  and antisense, inhibition of HCV replication by interferon- $\alpha$  or antisense oligonucleotides; transmission, transfer of HCV to naive cells by cocultivation with infected cells or incubation with medium from infected cells; IF, immunofluorescence; ISH, *in situ* hybridization; EM, detection of VLPs by electron microscopy; HVR sequence, determination of the nucleotide sequence of the hypervariable region.

‡ Number of days between infection and the last day of detection of HCV plus-strand RNA.

limited virus population replicates in MT-2C cells (Sugiyama *et al.*, 1997), suggesting the selection of certain variants particularly adapted to these cells. Long-term propagation of HCV for more than 1 year has been described for the human T- and B-cell lines HPB-Ma10-2 and Daudi (Nakajima *et al.*, 1996), and virus could be transmitted several times to naive cells by cocultivation (Shimizu & Yoshikura, 1994). To demonstrate infectivity of cell-culture-grown HCV in an animal, Shimizu *et al.* (1998) inoculated a chimpanzee with  $\sim 10^3$  genome equivalents present in the culture supernatants from Daudi cells that had been infected with HCV for 58 days. After  $\sim 5$  weeks HCV RNA became detectable in the serum of the animal and vanished after week 25. Interestingly, the major HVR1 sequence in the serum of the animal corresponded to the predominant variant in the patient serum used for infection of Daudi cells. However, in PBMCs of the chimpanzee the major variant corresponded to the dominant variant found in Daudi cells and this variant was not found in the inoculum patient

serum. These results suggest the selection of a lymphotropic HCV variant during cell culture passage.

### Transfection of cell lines with cloned HCV sequences

Compared to the infection of cell lines with HCV-containing patient material, the introduction of cloned virus genomes is superior because the inoculum is well defined and can be generated in high quantities. Most importantly, the genome can be manipulated at will, permitting a detailed genetic analysis of viral functions. Although the production of infectious virus from cells transfected with cRNA (RNA generated by *in vitro* transcription of a cloned DNA copy of the viral genome) has been described for several plus-strand RNA viruses (Boyer & Haenni, 1994), this approach turned out to be very difficult for HCV. Up to now only two reports have been published describing the replication of a transfected HCV genome in the human hepatoma cell lines Huh-7 or HepG2 (Dash *et al.*, 1997; Yoo *et al.*, 1995). However, in both studies




Fig. 3. Schematic representation of the method used to establish HCV-replicon-containing cell lines. The structure of the HCV genome is given at the top. The subgenomic RNAs derived therefrom, composed of the HCV 5' NTR plus a small fragment of the core-coding region (thin box), the *neo* gene, the encephalomyocarditis virus IRES (E-I), HCV NS2–5B or NS3–5B and the 3' NTR, are drawn below. Since core-coding sequences are required for full IRES activity, the ~ 20 amino-terminal residues of the core protein are fused to the amino terminus of the neomycin phosphotransferase. Upon transfection of Huh-7 cells, only those supporting replication of the HCV RNAs amplify the *neo* gene and develop resistance against the drug G418. Therefore, only these cells will form colonies, whereas untransfected cells and cells that do not support replication of these RNAs will be eliminated during the selection.

truncated HCV genomes were used that lacked the authentic 3' NTR. The replication competence of such genomes contradicts the finding that the highly conserved sequence at the very 3' end of the genome is essential for replication *in vivo* (Yanagi *et al.*, 1999; Kolykhalov *et al.*, 2000) and in cells transfected with selectable HCV replicons (unpublished results; see below). A clarification of this issue awaits the sequence analysis of the recloned 3' truncated RNAs and the successful infection of chimpanzees with culture medium from these cells.

Recently we have developed selectable subgenomic HCV RNA molecules replicating to high levels after transfection into the human hepatoma cell line Huh-7 (Lohmann *et al.*, 1999b). Based on the assumption that high expression levels of the structural proteins might be cytotoxic (Moradpour *et al.*,

1998) and the observation that for several plus-strand RNA viruses like alpha-, flavi- and pestiviruses the structural proteins are not required for RNA replication (Behrens *et al.*, 1998; Khromykh & Westaway, 1997; Liljestrom & Garoff, 1991), the sequences of the structural proteins were deleted. To allow selection for only those cells in which HCV will efficiently replicate, the gene encoding the neomycin phosphotransferase, conferring resistance to the antibiotic G418, was introduced downstream of the HCV IRES (Fig. 3). A second IRES element was included to allow translation of the HCV NS proteins. Since we did not know whether NS2 was required for replication, two variants were generated spanning the NS2–5B or the NS3–5B region. Upon transfection of these bicistronic RNAs and selection of the cells with G418, only those

supporting replication of these RNAs amplified the *neo* gene and developed resistance, whereas non-transfected cells and cells unable to support replication died. With this approach cell clones could be established with both the NS2–5B and the NS3–5B replicon, albeit with low efficiency. Surprisingly, these selected cells carried large amounts of HCV RNAs detectable by Northern blot, or after metabolic radiolabelling with <sup>3</sup>H]uridine, providing formal proof that these RNAs were actively replicating in the cells. Using these techniques we detected 1000–5000 RNA molecules per cell, which is several orders of magnitude higher compared to infection systems (Blight & Gowans, 1995). As expected for a replicative intermediate, minus-strand RNA was present in ~10-fold molar lower amounts compared to plus-strand RNA. HCV proteins could be detected by immunoprecipitation after metabolic radiolabelling with <sup>35</sup>S]methionine (Lohmann *et al.*, 1999 *b*) or Western blot (K. Kurpanek & R. Bartenschlager, unpublished results) and were confined to the cytoplasm.

A still unresolved question is why we only obtained colonies with the cell line Huh-7. Although intensive tests still have to be done, this result suggests that specific host cell factors present in only a few cell lines are required for HCV replication and possibly determine a narrow host range.

### Concluding remarks

Since the molecular cloning of the HCV genome only ca. 10 years have elapsed, but in this short period our knowledge about this insidious pathogen has increased tremendously. This rapid progress is best reflected by the resolution of the three-dimensional structures of the viral enzymes participating in polyprotein processing and replication: the NS3/4A proteinase, the NS3 helicase and the NS5B RdRp (Ago *et al.*, 1999; Bressanelli *et al.*, 1999; Kim *et al.*, 1996, 1998; Lesburg *et al.*, 1999; Love *et al.*, 1996; Yan *et al.*, 1998; Yao *et al.*, 1997). However, from what the field suffers most is the lack of a reproducible and efficient cell culture system. The recent demonstration of HCV replication and disease development after intrahepatic inoculation of chimpanzees with cloned virus genomes (Beard *et al.*, 1999; Kolykhalov *et al.*, 1997; Yanagi *et al.*, 1997, 1998) has opened some new avenues to study HCV replication and pathogenesis, but even for these genomes so far no cell culture system has been described. A first step in this direction is the development of selectable HCV replicons. Although this system still does not allow the production of infectious virus particles, it probably provides the framework to proceed towards this goal.

We are grateful to Jean Dubuisson for careful reading of the manuscript and helpful suggestions. Work in the author's laboratory was supported by grants from the Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (01 KI 9653/9), the Deutsche Forschungsgemeinschaft (BA1505/1-2) and Roche Products Ltd, Welwyn Garden City, UK.

### References

- Agnello, V., Abel, G., Elfahal, M., Knight, G. B. & Zhang, Q. X. (1999). Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. *Proceedings of the National Academy of Sciences, USA* **96**, 12766–12771.
- Ago, H., Adachi, T., Yoshida, A., Yamamoto, M., Habuka, N., Yatsunami, K. & Miyano, M. (1999). Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. *Structure with Folding and Design* **7**, 1417–1426.
- Al, R. H., Xie, Y. P., Wang, Y. H. & Hagedorn, C. H. (1998). Expression of recombinant hepatitis C virus non-structural protein 5B in *Escherichia coli*. *Virus Research* **53**, 141–149.
- Ali, N. & Siddiqui, A. (1995). Interaction of polypyrimidine tract-binding protein with the 5' noncoding region of the hepatitis C virus RNA genome and its functional requirement in internal initiation of translation. *Journal of Virology* **69**, 6367–6375.
- Ali, N. & Siddiqui, A. (1997). The La antigen binds 5' noncoding region of the hepatitis C virus RNA in the context of the initiator AUG codon and stimulates internal ribosome entry site-mediated translation. *Proceedings of the National Academy of Sciences, USA* **94**, 2249–2254.
- Asabe, S. I., Tanji, Y., Satoh, S., Kaneko, T., Kimura, K. & Shimotohno, K. (1997). The N-terminal region of hepatitis C virus-encoded NS5A is important for NS4A-dependent phosphorylation. *Journal of Virology* **71**, 790–796.
- Barbato, G., Cicero, D. O., Nardi, M. C., Steinkühler, C., Cortese, R., De Francesco, R. & Bazzo, R. (1999). The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. *Journal of Molecular Biology* **289**, 371–384.
- Barik, S. & Banerjee, A. K. (1992). Sequential phosphorylation of the phosphoprotein of vesicular stomatitis virus by cellular and viral protein kinases is essential for transcription activation. *Journal of Virology* **66**, 1109–1118.
- Bartenschlager, R. (1999). The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. *Journal of Viral Hepatitis* **6**, 165–181.
- Bartenschlager, R., Ahlborn-Laake, L., Mous, J. & Jacobsen, H. (1993). Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. *Journal of Virology* **67**, 3835–3844.
- Bartenschlager, R., Ahlborn-Laake, L., Mous, J. & Jacobsen, H. (1994). Kinetic and structural analyses of hepatitis C virus polyprotein processing. *Journal of Virology* **68**, 5045–5055.
- Bartenschlager, R., Lohmann, V., Wilkinson, T. & Koch, J. O. (1995). Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. *Journal of Virology* **69**, 7519–7528.
- Baumert, T. F., Ito, S., Wong, D. T. & Liang, T. J. (1998). Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. *Journal of Virology* **72**, 3827–3836.
- Beard, M. R., Abell, G., Honda, M., Carroll, A., Gartland, M., Clarke, B., Suzuki, K., Lanford, R., Sangar, D. V. & Lemon, S. M. (1999). An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. *Hepatology* **30**, 316–324.
- Behrens, S. E., Tomei, L. & De Francesco, R. (1996). Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. *EMBO Journal* **15**, 12–22.
- Behrens, S. E., Grassmann, C. W., Thiel, H. J., Meyers, G. & Tautz, N.

- (1998). Characterization of an autonomous subgenomic pestivirus RNA replicon. *Journal of Virology* **72**, 2364–2372.
- Bertolini, L., Iacovacci, S., Ponzetto, A., Gorini, G., Battaglia, M. & Carloni, G. (1993).** The human bone-marrow-derived B-cell line CE, susceptible to hepatitis C virus infection. *Research in Virology* **144**, 281–285.
- Blight, K. & Gowans, E. (1995).** In situ hybridization and immunohistochemical staining of hepatitis C virus products. *Viral Hepatitis Reviews* **1**, 143–155.
- Bolten, R., Egger, D., Gosert, R., Schaub, G., Landmann, L. & Bienz, K. (1998).** Intracellular localization of poliovirus plus- and minus-strand RNA visualized by strand-specific fluorescent in situ hybridization. *Journal of Virology* **72**, 8578–8585.
- Borowski, P., Heiland, M., Oehlmann, K., Becker, B., Kornetzky, L., Feucht, H. & Laufs, R. (1996).** Non-structural protein 3 of hepatitis C virus inhibits phosphorylation mediated by cAMP-dependent protein kinase. *European Journal of Biochemistry* **237**, 611–618.
- Bouffard, P., Hayashi, P. H., Acevedo, R., Levy, N. & Zeldis, J. B. (1992).** Hepatitis C virus is detected in a monocyte/macrophage subpopulation of peripheral blood mononuclear cells of infected patients. *Journal of Infectious Diseases* **166**, 1276–1280.
- Boyer, J. C. & Haenni, A. L. (1994).** Infectious transcripts and cDNA clones of RNA viruses. *Virology* **198**, 415–426.
- Bressanelli, S., Tomei, L., Roussel, A., Incitti, I., Vitale, R. L., Mathieu, M., De Francesco, R. & Rey, F. A. (1999).** Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. *Proceedings of the National Academy of Sciences, USA* **96**, 13034–13039.
- Bukh, J., Apgar, C. L. & Yanagi, M. (1999).** Toward a surrogate model for hepatitis C virus: an infectious molecular clone of the GB virus-B hepatitis agent. *Virology* **262**, 470–478.
- Butkiewicz, N. J., Wendel, M., Zhang, R., Jubin, R., Pichardo, J., Smith, E. B., Hart, A. M., Ingram, R., Durkin, J., Mui, P. W., Murray, M. G., Ramanathan, L. & Dasmahapatra, B. (1996).** Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity. *Virology* **225**, 328–338.
- Chang, J., Yang, S. H., Cho, Y. G., Hwang, S. B., Hahn, Y. S. & Sung, Y. C. (1998).** Hepatitis C virus core from two different genotypes has an oncogenic potential but is not sufficient for transforming primary rat embryo fibroblasts in cooperation with the H-ras oncogene. *Journal of Virology* **72**, 3060–3065.
- Chen, C. M., You, L. R., Hwang, L. H. & Lee, Y. H. (1997).** Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor. *Journal of Virology* **71**, 9417–9426.
- Cheng, J.-U., Chang, M.-F. & Chang, S. C. (1999).** Specific interaction between the hepatitis C virus NS5B RNA polymerase and the 3' end of the viral RNA. *Journal of Virology* **73**, 7044–7049.
- Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W. & Houghton, M. (1989).** Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* **244**, 359–362.
- Chung, R. T. & Kaplan, L. M. (1999).** Heterogeneous nuclear ribonucleoprotein I (hnRNP-I/PTB) selectively binds the conserved 3' terminus of hepatitis C viral RNA. *Biochemical and Biophysical Research Communications* **254**, 351–362.
- Cocquerel, L., Duvet, S., Meunier, J. C., Pillez, A., Cacan, R., Wychowski, C. & Dubuisson, J. (1999).** The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. *Journal of Virology* **73**, 2641–2649.
- Cribier, B., Schmitt, C., Bingen, A., Kirn, A. & Keller, F. (1995).** *In vitro* infection of peripheral blood mononuclear cells by hepatitis C virus. *Journal of General Virology* **76**, 2485–2491.
- Dash, S., Halim, A. B., Tsuji, H., Hiramatsu, N. & Gerber, M. A. (1997).** Transfection of HepG2 cells with infectious hepatitis C virus genome. *American Journal of Pathology* **151**, 363–373.
- De Francesco, R., Behrens, S.-E., Tomei, L., Altamura, S. & Jiricny, J. (1996a).** RNA-dependent RNA polymerase of hepatitis C virus. *Methods in Enzymology* **275**, 58–67.
- De Francesco, R., Urbani, A., Nardi, M. C., Tomei, L., Steinkühler, C. & Tramontano, A. (1996b).** A zinc binding site in viral serine proteinases. *Biochemistry* **35**, 13282–13287.
- De Francesco, R., Pessi, A. & Steinkühler, C. (1998).** The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase. In *Therapies for Viral Hepatitis*, pp. 235–245. Edited by R. F. Schinazi, J.-P. Sommadossi & H. C. Thomas. London: International Medical Press.
- Deleersnyder, V., Pillez, A., Wychowski, C., Blight, K., Xu, J., Hahn, Y. S., Rice, C. M. & Dubuisson, J. (1997).** Formation of native hepatitis C virus glycoprotein complexes. *Journal of Virology* **71**, 697–704.
- Dubuisson, J., Hsu, H. H., Cheung, R. C., Greenberg, H. B., Russell, D. G. & Rice, C. M. (1994).** Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. *Journal of Virology* **68**, 6147–6160.
- Duvet, S., Cocquerel, L., Pillez, A., Cacan, R., Verbert, A., Moradpour, D., Wychowski, C. & Dubuisson, J. (1999).** Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. *Journal of Biological Chemistry* **273**, 32088–32095.
- Eckart, M. R., Selby, M., Masiarz, F., Lee, C., Berger, K., Crawford, K., Kuo, C., Kuo, G., Houghton, M. & Choo, Q. L. (1993).** The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. *Biochemical and Biophysical Research Communications* **192**, 399–406.
- Esteban, J. I., Cordoba, J. & Saucedo, S. (1998).** The clinical picture of acute and chronic hepatitis C. In *Hepatitis C Virus*, 2nd edn, pp. 102–118. Edited by H. W. Reesink. Basel, Switzerland: Karger.
- Failla, C., Tomei, L. & De Francesco, R. (1994).** Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. *Journal of Virology* **68**, 3753–3760.
- Failla, C., Tomei, L. & De Francesco, R. (1995).** An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A. *Journal of Virology* **69**, 1769–1777.
- Farci, P., Shimoda, A., Wong, D., Cabezon, T., Gioannis, D., Strazzer, A., Shimizu, Y., Shapiro, M., Alter, H. J. & Purcell, R. H. (1996).** Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. *Proceedings of the National Academy of Sciences, USA* **93**, 15394–15399.
- Ferrari, E., Wright, M. J., Fang, J. W., Baroudy, B. M., Lau, J. Y. & Hong, Z. (1999).** Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in *Escherichia coli*. *Journal of Virology* **73**, 1649–1654.
- Flint, M., Thomas, J., Maidens, C., Shotton, C., Levy, S., Barclay, W. & McKeating, J. A. (1999).** Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. *Journal of Virology* **73**, 6782–6790.
- Fournier, C., Sureau, C., Coste, J., Ducos, J., Pageaux, G., Larrey, D., Domergue, J. & Maurel, P. (1998).** *In vitro* infection of adult normal human hepatocytes in primary culture by hepatitis C virus. *Journal of General Virology* **79**, 2367–2374.



- Fukushi, S., Katayama, K., Kurihara, C., Ishiyama, N., Hoshino, F. B., Ando, T. & Oya, A. (1994). Complete 5' noncoding region is necessary for the efficient internal initiation of hepatitis C virus RNA. *Biochemical and Biophysical Research Communications* **199**, 425–432.
- Fukushi, S., Kurihara, C., Ishiyama, N., Hoshino, F. B., Oya, A. & Katayama, K. (1997). The sequence element of the internal ribosome entry site and a 25-kilodalton cellular protein contribute to efficient internal initiation of translation of hepatitis C virus RNA. *Journal of Virology* **71**, 1662–1666.
- Gale, M. J., Korth, M. J., Tang, N. M., Tan, S. L., Hopkins, D. A., Dever, T. E., Polyak, S. J., Gretch, D. R. & Katze, M. G. (1997). Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. *Virology* **230**, 217–227.
- Gale, M. J., Jr, Blakely, S. M., Kwiciszewski, B., Tan, S.-L., Dossett, M., Tang, N. M., Korth, M. J., Polyak, S. J., Gretch, D. R. & Katze, M. G. (1998). Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanism of kinase regulation. *Molecular and Cellular Biology* **18**, 5208–5218.
- Gallinari, P., Brennan, D., Nardi, C., Brunetti, M., Tomei, L., Steinkühler, C. & De Francesco, R. (1998). Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. *Journal of Virology* **72**, 6758–6769.
- Gorbalenya, A. E. & Snijder, E. J. (1998). Viral cysteine proteinases. *Perspectives in Drug Discovery and Design* **6**, 64–86.
- Grakoui, A., McCourt, D. W., Wychowski, C., Feinstone, S. M. & Rice, C. M. (1993a). A second hepatitis C virus-encoded proteinase. *Proceedings of the National Academy of Sciences, USA* **90**, 10583–10587.
- Grakoui, A., McCourt, D. W., Wychowski, C., Feinstone, S. M. & Rice, C. M. (1993b). Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. *Journal of Virology* **67**, 2832–2843.
- Gunji, T., Kato, N., Hijikata, M., Hayashi, K., Saitoh, S. & Shimotohno, K. (1994). Specific detection of positive and negative stranded hepatitis C viral RNA using chemical RNA modification. *Archives of Virology* **134**, 293–302.
- Gwack, Y., Kim, D. W., Han, J. H. & Choe, J. (1996). Characterization of RNA binding activity and RNA helicase activity of the hepatitis C virus NS3 protein. *Biochemical and Biophysical Research Communications* **225**, 654–659.
- Hahm, B., Kim, Y. K., Kim, J. H., Kim, T. Y. & Jang, S. K. (1998). Heterogeneous nuclear ribonucleoprotein L interacts with the 3' border of the internal ribosomal entry site of hepatitis C virus. *Journal of Virology* **72**, 8782–8788.
- Hijikata, M., Kato, N., Ootsuyama, Y., Nakagawa, M. & Shimotohno, K. (1991). Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. *Proceedings of the National Academy of Sciences, USA* **88**, 5547–5551.
- Hijikata, M., Mizushima, H., Akagi, T., Mori, S., Kakiuchi, N., Kato, N., Tanaka, T., Kimura, K. & Shimotohno, K. (1993a). Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. *Journal of Virology* **67**, 4665–4675.
- Hijikata, M., Mizushima, H., Tanji, Y., Komoda, Y., Hirowatari, Y., Akagi, T., Kato, N., Kimura, K. & Shimotohno, K. (1993b). Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. *Proceedings of the National Academy of Sciences, USA* **90**, 10773–10777.
- Hirowatari, Y., Hijikata, M., Tanji, Y., Nyunoya, H., Mizushima, H., Kimura, K., Tanaka, T., Kato, N. & Shimotohno, K. (1993). Two proteinase activities in HCV polypeptide expressed in insect cells using baculovirus vector. *Archives of Virology* **133**, 349–356.
- Holland, J. J., De La Torre, J. C. & Steinhauer, D. A. (1992). RNA virus populations as quasispecies. *Current Topics in Microbiology and Immunology* **176**, 1–20.
- Honda, M., Ping, L. H., Rijnbrand, R. A., Amphlett, E., Clarke, B., Rowlands, D. & Lemon, S. M. (1996). Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA. *Virology* **222**, 31–42.
- Honda, M., Kaneko, S., Matsushita, E., Kobayashi, K., Abell, G. & Lemon, S. (2000). Cell cycle regulation of hepatitis C virus internal ribosome entry site-directed translation. *Gastroenterology* **118**, 152–162.
- Hong, Z., Ferrari, E., Wright-Minogue, J., Chase, R., Risano, C., Seelig, G., Lee, C. G. & Kwong, A. D. (1996). Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system. *Journal of Virology* **70**, 4261–4268.
- Howe, A. Y., Chase, R., Taremi, S. S., Risano, C., Beyer, B., Malcolm, B. & Lau, J. Y. (1999). A novel recombinant single-chain hepatitis C virus NS3–NS4A protein with improved helicase activity. *Protein Science* **8**, 1332–1341.
- Hüssy, P., Langen, H., Mous, J. & Jacobsen, H. (1996). Hepatitis C virus core protein: carboxy-terminal boundaries of two processed species suggest cleavage by a signal peptide peptidase. *Virology* **224**, 93–104.
- Iacovacci, S., Sargiacomo, M., Parolini, I., Ponzetto, A., Peschle, C. & Carloni, G. (1993). Replication and multiplication of hepatitis C virus genome in human foetal liver cells. *Research in Virology* **144**, 275–279.
- Ide, Y., Tanimoto, A., Sasaguri, Y. & Padmanabhan, R. (1997). Hepatitis C virus NS5A protein is phosphorylated in vitro by a stably bound protein kinase from HeLa cells and by cAMP-dependent protein kinase A-alpha catalytic subunit. *Gene* **201**, 151–158.
- Ikeda, M., Sugiyama, K., Mizutani, T., Tanaka, T., Tanaka, K., Sekihara, H., Shimotohno, K. & Kato, N. (1998). Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. *Virus Research* **56**, 157–167.
- Ilan, E., Burakova, T., Dagan, S., Nussbaum, O., Lubin, I., Eren, R., Ben, M. O., Arazi, J., Berr, S., Neville, L., Yuen, L., Mansour, T. S., Gillard, J., Eid, A., Jurim, O., Shouval, D., Reisner, Y. & Galun, E. (1999). The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. *Hepatology* **29**, 553–562.
- Inoue, Y., Miyazaki, M., Ohashi, R., Tsuji, T., Fukaya, K., Kouchi, H., Uemura, T., Mihara, K. & Namba, M. (1998). Ubiquitous presence of cellular proteins that specifically bind to the 3' terminal region of hepatitis C virus. *Biochemical and Biophysical Research Communications* **245**, 198–203.
- Ishido, S., Fujita, T. & Hotta, H. (1998). Complex formation of NS5B with NS3 and NS4A proteins of hepatitis C virus. *Biochemical and Biophysical Research Communications* **244**, 35–40.
- Ito, T. & Lai, M. C. (1997). Determination of the secondary structure of and cellular protein binding to the 3'-untranslated region of the hepatitis C virus RNA genome. *Journal of Virology* **71**, 8698–8706.
- Ito, T., Mukaigawa, J., Zuo, J., Hirabayashi, Y., Mitamura, K. & Yasui, K. (1996). Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus. *Journal of General Virology* **77**, 1043–1054.
- Ito, T., Tahara, S. M. & Lai, M. C. (1998). The 3'-untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site. *Journal of Virology* **72**, 8789–8796.

- Kaminski, A., Hunt, S. L., Patton, J. G. & Jackson, R. J. (1995). Direct evidence that polypyrimidine tract binding protein (PTB) is essential for internal initiation of translation of encephalomyocarditis virus RNA. *RNA* **1**, 924–938.
- Kaneko, T., Tanji, Y., Satoh, S., Hijikata, M., Asabe, S., Kimura, K. & Shimotohno, K. (1994). Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. *Biochemical and Biophysical Research Communications* **205**, 320–326.
- Kao, C. C., DelVecchio, A. & Zhong, W. (1999). De novo initiation of RNA synthesis by a recombinant Flaviviridae RNA-dependent RNA polymerase. *Virology* **253**, 1–7.
- Kapoor, M., Zhang, L., Ramachandra, M., Kuskawa, J., Ebner, K. E. & Padmanabhan, R. (1995). Association between NS3 and NS5 proteins of dengue virus type 2 in the putative RNA replicase is linked to differential phosphorylation of NS5. *Journal of Biological Chemistry* **270**, 19100–19106.
- Kato, N., Nakazawa, T., Mizutani, T. & Shimotohno, K. (1995). Susceptibility of human T-lymphotropic virus type I infected cell line MT-2 to hepatitis C virus infection. *Biochemical and Biophysical Research Communications* **206**, 863–869.
- Kato, N., Ikeda, M., Mizutani, T., Sugiyama, K., Noguchi, M., Hirohashi, S. & Shimotohno, K. (1996). Replication of hepatitis C virus in cultured non-neoplastic human hepatocytes. *Japanese Journal of Cancer Research* **87**, 787–792.
- Khromykh, A. A. & Westaway, E. G. (1997). Subgenomic replicons of the flavivirus Kunjin: construction and applications. *Journal of Virology* **71**, 1497–1505.
- Kim, D. W., Gwack, Y., Han, J. H. & Choe, J. (1995). C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. *Biochemical and Biophysical Research Communications* **215**, 160–166.
- Kim, J. L., Morgenstern, K. A., Lin, C., Fox, T., Dwyer, M. D., Landro, J. A., Chambers, S. P., Markland, W., Lepre, C. A., O'Malley, E. T., Harbeson, S. L., Rice, C. M., Murcko, M. A., Caron, P. R. & Thomson, J. A. (1996). Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. *Cell* **87**, 343–355.
- Kim, J. L., Morgenstern, K. A., Griffith, J. P., Dwyer, M. D., Thomson, J. A., Murcko, M. A., Lin, C. & Caron, P. R. (1998). Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. *Structure* **6**, 89–100.
- Koch, J. O. & Bartenschlager, R. (1999). Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B. *Journal of Virology* **73**, 7138–7146.
- Koch, J. O., Lohmann, V., Herian, U. & Bartenschlager, R. (1996). In vitro studies on the activation of the hepatitis C virus NS3 proteinase by the NS4A cofactor. *Virology* **221**, 54–66.
- Kolykhalov, A. A., Feinstone, S. M. & Rice, C. M. (1996). Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA. *Journal of Virology* **70**, 3363–3371.
- Kolykhalov, A. A., Agapov, E. V., Blight, K. J., Mihalik, K., Feinstone, S. M. & Rice, C. M. (1997). Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. *Science* **277**, 570–574.
- Kolykhalov, A. A., Mihalik, K., Feinstone, S. M. & Rice, C. M. (2000). Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated-region are essential for virus replication in vivo. *Journal of Virology* **74**, 2046–2051.
- Lagging, L. M., Meyer, K., Owens, R. J. & Ray, R. (1998). Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. *Journal of Virology* **72**, 3539–3546.
- Lanford, R. E., Sureau, C., Jacob, J. R., White, R. & Fuerst, T. R. (1994). Demonstration of in vitro infection of chimpanzee hepatocytes with hepatitis C virus using strand-specific RT/PCR. *Virology* **202**, 606–614.
- Lanford, R. E., Chavez, D., Chisari, F. V. & Sureau, C. (1995). Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR. *Journal of Virology* **69**, 8079–8083.
- Laskus, T., Radkowski, M., Wang, L.-F., Cianciara, J., Vargas, H. & Rakela, J. (1997). Hepatitis C virus negative strand RNA is not detected in peripheral blood mononuclear cells and viral sequences are identical to those in serum: a case against extrahepatic replication. *Journal of General Virology* **78**, 2747–2750.
- Lavanchy, D., Purcell, R., Hollinger, F. B., Howard, C., Alberti, A., Kew, M., Dusheiko, G., Alter, M., Ayoola, E., Beutels, P., Bloomer, R., Ferret, B., Decker, R., Esteban, R., Fay, O., Fields, H., Fuller, E. C., Grob, P., Houghton, M., Leung, N., Locarnini, S. A., Margolis, H., Meheus, A., Miyamura, T., Mohamed, M. K., Tandon, B., Thomas, D., Head, H. T., Toukan, A. U., Van, D. P., Zanetti, A., Arthur, R., Couper, M., D'Amelio, R., Emmanuel, J. C., Esteves, K., Gavinio, P., Griffiths, E., Hallaj, Z., Heuck, C. C., Heymann, D. L., Holck, S. E., Kane, M., Martinez, L. J., Meslin, F., Mochny, I. S., Ndikuyeze, A., Padilla, A. M., Rodier, G. M., Roure, C., Savage, F. & Vercauteren, G. (1999). Global surveillance and control of hepatitis C. *Journal of Viral Hepatitis* **6**, 35–47.
- Lerat, H., Berby, F., Trabaud, M. A., Vidalin, O., Major, M., Trepo, C. & Inchauspe, G. (1996). Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. *Journal of Clinical Investigation* **97**, 845–851.
- Lesburg, C. A., Cable, M. B., Ferrari, E., Hong, Z., Mannarino, A. F. & Weber, P. C. (1999). Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. *Nature Structural Biology* **6**, 937–943.
- Liljestrom, P. & Garoff, H. (1991). A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. *Bio-technology* **9**, 1356–1361.
- Lin, C., Lindenbach, B. D., Pragai, B. M., McCourt, D. W. & Rice, C. M. (1994a). Processing in the hepatitis C virus E2–NS2 region: identification of p7 and two distinct E2-specific products with different C termini. *Journal of Virology* **68**, 5063–5073.
- Lin, C., Pragai, B. M., Grakoui, A., Xu, J. & Rice, C. M. (1994b). Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics. *Journal of Virology* **68**, 8147–8157.
- Lin, C., Thomson, J. A. & Rice, C. M. (1995). A central region in the hepatitis C virus NS4A protein allows formation of an active NS3–NS4A serine proteinase complex in vivo and in vitro. *Journal of Virology* **69**, 4373–4380.
- Lin, C., Wu, J. W., Hsiao, K. & Su, M. S. (1997). The hepatitis C virus NS4A protein: interactions with the NS4B and NS5A proteins. *Journal of Virology* **71**, 6465–6471.
- Lohmann, V., Körner, F., Herian, U. & Bartenschlager, R. (1997). Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. *Journal of Virology* **71**, 8416–8428.
- Lohmann, V., Overton, H. & Bartenschlager, R. (1999a). Selective stimulation of hepatitis C virus and pestivirus NS5B RNA polymerase activity by GTP. *Journal of Biological Chemistry* **274**, 10807–10815.
- Lohmann, V., Körner, F., Koch, J. O., Herian, U., Theilmann, L. & Bartenschlager, R. (1999b). Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* **285**, 110–113.

- Love, R. A., Parge, H. E., Wickersham, J. A., Hostomsky, Z., Habuka, N., Moomaw, E. W., Adachi, T. & Hostomska, Z. (1996). The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. *Cell* **87**, 331–342.
- Love, R. A., Parge, H. E., Wickersham, J. A., Hostomsky, Z., Habuka, N., Moomaw, E. W., Adachi, T., Margosiak, S., Dagostino, E. & Hostomska, Z. (1998). The conformation of hepatitis C virus NS3 proteinase with and without NS4A: a structural basis for the activation of the enzyme by its cofactor. *Clinical and Diagnostic Virology* **10**, 151–156.
- Luo, G., Hamatake, R. K., Mathis, D. M., Racela, J., Rigat, K. L., Lemm, J. & Colonno, R. J. (2000). De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus. *Journal of Virology* **74**, 851–863.
- Martell, M., Esteban, J. I., Quer, J., Genesca, J., Weiner, A., Esteban, R., Guardia, J. & Gomez, J. (1992). Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. *Journal of Virology* **66**, 3225–3229.
- Matsumoto, M., Hwang, S. B., Jeng, K. S., Zhu, N. & Lai, M. C. (1996). Homotypic interaction and multimerization of hepatitis C virus core protein. *Virology* **218**, 43–51.
- Matsumoto, M., Hsieh, T. Y., Zhu, N., Van Arsdale, T., Hwang, S. B., Jeng, K. S., Gorbalenya, A. E., Lo, S. Y., Ou, J. H., Ware, C. F. & Lai, M. C. (1997). Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. *Journal of Virology* **71**, 1301–1309.
- Mendez, E., Ruggli, N., Collett, M. S. & Rice, C. M. (1998). Infectious bovine viral diarrhoea virus (strain NADL) RNA from stable cDNA clones: a cellular insert determines NS3 production and viral cytopathogenicity. *Journal of Virology* **72**, 4737–4745.
- Meyers, G., Tautz, N., Becher, P., Thiel, H.-J. & Kümmerer, B. M. (1996). Recovery of cytopathogenic and noncytopathogenic bovine viral diarrhoea viruses from cDNA constructs. *Journal of Virology* **70**, 8606–8613.
- Michalak, J.-P., Wychowski, C., Choukhi, A., Meunier, J.-C., Ung, S., Rice, C. M. & Dubuisson, J. (1997). Characterization of truncated forms of hepatitis C virus glycoproteins. *Journal of General Virology* **78**, 2299–2306.
- Mizuno, M., Yamada, G., Tanaka, T., Shimotohno, K., Takatani, M. & Tsuji, T. (1995). Virion-like structures in HeLa G cells transfected with the full-length sequence of the hepatitis C virus genome. *Gastroenterology* **109**, 1933–1940.
- Mizushima, H., Hijikata, M., Asabe, S., Hirota, M., Kimura, K. & Shimotohno, K. (1994). Two hepatitis C virus glycoprotein E2 products with different C termini. *Journal of Virology* **68**, 6215–6222.
- Mizutani, T., Kato, N., Ikeda, M., Sugiyama, K. & Shimotohno, K. (1996a). Long-term human T-cell culture system supporting hepatitis C virus replication. *Biochemical and Biophysical Research Communications* **227**, 822–826.
- Mizutani, T., Kato, N., Saito, S., Ikeda, M., Sugiyama, K. & Shimotohno, K. (1996b). Characterization of hepatitis C virus replication in cloned cells obtained from a human T-cell leukemia virus type I-infected cell line, MT-2. *Journal of Virology* **70**, 7219–7223.
- Monazahian, M., Bohme, I., Bonk, S., Koch, A., Scholz, C., Grethe, S. & Thomssen, R. (1999). Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. *Journal of Medical Virology* **57**, 223–229.
- Moormann, R. J. M., van Gennip, H. G. P., Miedema, G. K. W., Hulst, M. M. & van Rijn, P. A. (1996). Infectious RNA transcribed from an engineered full-length cDNA template of the genome of a pestivirus. *Journal of Virology* **70**, 763–770.
- Moradpour, D., Wakita, T., Wands, J. R. & Blum, H. E. (1998). Tightly regulated expression of the entire hepatitis C virus structural region in continuous human cell lines. *Biochemical and Biophysical Research Communications* **246**, 920–924.
- Moriya, K., Fujie, H., Shintani, Y., Yotsuyanagi, H., Tsutsumi, T., Ishibashi, K., Matsuura, Y., Kimura, S., Miyamura, T. & Koike, K. (1998). The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *Nature Medicine* **4**, 1065–1067.
- Müller, H. M., Pfaff, E., Goeser, T., Kallinowski, B., Solbach, C. & Theilmann, L. (1993). Peripheral blood leukocytes serve as a possible extrahepatic site for hepatitis C virus replication. *Journal of General Virology* **74**, 669–676.
- Murphy, F. A., Fauquet, C. M., Bishop, D. H. L., Ghabrial, S. A., Jarvis, A. W., Martelli, G. P., Mayo, M. A. & Summers, M. D. (editors) (1995). *Virus Taxonomy. Sixth Report of the International Committee on Taxonomy of Viruses*, pp. 424–426. Vienna & New York: Springer-Verlag.
- Nakajima, N., Hijikata, M., Yoshikura, H. & Shimizu, Y. K. (1996). Characterization of long-term cultures of hepatitis C virus. *Journal of Virology* **70**, 3325–3329.
- Neddermann, P., Clementi, A. & De Francesco, R. (1999). Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein. *Journal of Virology* **73**, 9984–9991.
- Neumann, A. U., Lam, N. P., Dahari, H., Gretch, D. R., Wiley, T. E., Layden, T. J. & Perelson, A. S. (1998). Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. *Science* **282**, 103–107.
- Nolandt, O., Kern, V., Müller, H., Pfaff, E., Theilmann, L., Welker, R. & Kräusslich, H.-G. (1997). Analysis of hepatitis C virus core protein interaction domains. *Journal of General Virology* **78**, 1331–1340.
- Novak, J. E. & Kirkegaard, K. (1994). Coupling between genome translation and replication in an RNA virus. *Genes & Development* **8**, 1726–1737.
- Ogata, N., Alter, H. J., Miller, R. H. & Purcell, R. H. (1991). Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. *Proceedings of the National Academy of Sciences, USA* **88**, 3392–3396.
- Oh, J. W., Ito, T. & Lai, M. C. (1999). A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full-length viral RNA. *Journal of Virology* **73**, 7694–7702.
- Okamoto, H., Kojima, M., Okada, S., Yoshizawa, H., Iizuka, H., Tanaka, T., Muchmore, E. E., Peterson, D. A., Ito, Y. & Mishiro, S. (1992). Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. *Virology* **190**, 894–899.
- Pestova, T. V., Shatsky, I. N., Fletcher, S. P., Jackson, R. J. & Hellen, C. U. (1998). A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. *Genes & Development* **12**, 67–83.
- Petersen, J., Dandri, M., Gupta, S. & Rogler, C. E. (1998). Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepatitis B infection and clonal growth of hepatocellular carcinoma. *Proceedings of the National Academy of Sciences, USA* **95**, 310–315.
- Petrik, J., Parker, H. & Alexander, G. J. M. (1999). Human hepatic glyceraldehyde-3-phosphate dehydrogenase binds to the poly(U) tract of the 3' non-coding region of hepatitis C virus genomic RNA. *Journal of General Virology* **80**, 3109–3113.
- Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R., Weiner, A. J., Houghton, M., Rosa, D., Grandi, G. & Abrignani, S. (1998). Binding of hepatitis C virus to CD81. *Science* **282**, 938–941.



- Ramratnam, B., Bonhoeffer, S., Binley, J., Hurley, A., Zhang, L. Q., Mittler, J. E., Markowitz, M., Moore, J. P., Perelson, A. S. & Ho, D. D. (1999). Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. *Lancet* **354**, 1782–1785.
- Reed, K. E. & Rice, C. M. (1998). Molecular characterization of hepatitis C virus. In *Hepatitis C Virus*, 2nd edn, pp. 1–37. Edited by H. W. Reesink. Basel, Switzerland: Karger.
- Reed, K. E. & Rice, C. M. (1999). Identification of the major phosphorylation site of the hepatitis C virus H strain NS5A protein as serine 2321. *Journal of Biological Chemistry* **274**, 28011–28018.
- Reed, K. E., Xu, J. & Rice, C. M. (1997). Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase. *Journal of Virology* **71**, 7187–7197.
- Reed, K. E., Gorbalenya, A. E. & Rice, C. M. (1998). The NS5A/NS5 proteins of viruses from three genera of the family Flaviviridae are phosphorylated by associated serine/threonine kinases. *Journal of Virology* **72**, 6199–6206.
- Reynolds, J. E., Kaminski, A., Kettinen, H. J., Grace, K., Clarke, B. E., Carroll, A. R., Rowlands, D. J. & Jackson, R. J. (1995). Unique features of internal initiation of hepatitis C virus RNA translation. *EMBO Journal* **14**, 6010–6020.
- Reynolds, J. E., Kaminski, A., Carroll, A. R., Clarke, B. E., Rowlands, D. J. & Jackson, R. J. (1996). Internal initiation of translation of hepatitis C virus RNA: the ribosome entry site is at the authentic initiation codon. *RNA* **2**, 867–878.
- Rijnbrand, R., Bredenbeek, P., van der Straaten, T., Whetter, L., Inchauspe, G., Lemon, S. & Spaan, W. (1995). Almost the entire 5' nontranslated region of hepatitis C virus is required for cap-independent translation. *FEBS Letters* **365**, 115–119.
- Rijnbrand, R. C., Abbink, T. E., Haasnoot, P. C., Spaan, W. J. & Bredenbeek, P. J. (1996). The influence of AUG codons in the hepatitis C virus 5' nontranslated region on translation and mapping of the translation initiation window. *Virology* **226**, 47–56.
- Rosa, D., Campagnoli, S., Moretto, C., Guenzi, E., Cousens, L., Chin, M., Dong, C., Weiner, A. J., Lau, J. Y. N., Choo, Q. L., Chien, D., Pileri, P., Houghton, M. & Abrignani, S. (1996). A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. *Proceedings of the National Academy of Sciences, USA* **93**, 1759–1763.
- Ruggli, N., Tratschin, J.-D., Mittelholzer, C. & Hofmann, M. (1996). Nucleotide sequence of classical swine fever virus strain Alfort/187 and transcription of infectious RNA from stably cloned full-length cDNA. *Journal of Virology* **70**, 3478–3487.
- Rumin, S., Berthillon, P., Tanaka, E., Kiyosawa, K., Trabaud, M.-A., Bizollon, T., Gouillat, C., Gripon, P., Guguen-Guillouzo, C., Inchauspe, G. & Trepo, C. (1999). Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected *in vitro*. *Journal of General Virology* **80**, 3007–3018.
- Sakamuro, D., Furukawa, T. & Takegami, T. (1995). Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. *Journal of Virology* **69**, 3893–3896.
- Santolini, E., Migliaccio, G. & LaMonica, N. (1994). Biosynthesis and biochemical properties of the hepatitis C virus core protein. *Journal of Virology* **68**, 3631–3641.
- Santolini, E., Pacini, L., Fipaldini, C., Migliaccio, G. & LaMonica, N. (1995). The NS2 protein of hepatitis C virus is a transmembrane polypeptide. *Journal of Virology* **69**, 7461–7471.
- Sato, K., Okamoto, H., Aihara, S., Hoshi, Y., Tanaka, T. & Mishiro, S. (1993). Demonstration of sugar moiety on the surface of hepatitis C virions recovered from the circulation of infected humans. *Virology* **196**, 354–357.
- Satoh, S., Tanji, Y., Hijikata, M., Kimura, K. & Shimotohno, K. (1995). The N-terminal region of hepatitis C virus nonstructural protein 3 (NS3) is essential for stable complex formation with NS4A. *Journal of Virology* **69**, 4255–4260.
- Seipp, S., Müller, H. M., Pfaff, E., Stremmel, W., Theilmann, L. & Goeser, T. (1997). Establishment of persistent hepatitis C virus infection and replication *in vitro*. *Journal of General Virology* **78**, 2467–2476.
- Shimizu, Y. K. & Yoshikura, H. (1994). Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons. *Journal of Virology* **68**, 8406–8408.
- Shimizu, Y. K., Iwamoto, A., Hijikata, M., Purcell, R. H. & Yoshikura, H. (1992). Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. *Proceedings of the National Academy of Sciences, USA* **89**, 5477–5481.
- Shimizu, Y. K., Purcell, R. H. & Yoshikura, H. (1993). Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro. *Proceedings of the National Academy of Sciences, USA* **90**, 6037–6041.
- Shimizu, Y., Yamaji, K., Masuho, Y., Yokota, T., Inoue, H., Sudo, K., Satoh, S. & Shimotohno, K. (1996a). Identification of the sequence on NS4A required for enhanced cleavage of the NS5A/5B site by hepatitis C virus NS3 protease. *Journal of Virology* **70**, 127–132.
- Shimizu, Y. K., Feinstone, S. M., Kohara, M., Purcell, R. H. & Yoshikura, H. (1996b). Hepatitis C virus: detection of intracellular virus particles by electron microscopy. *Hepatology* **23**, 205–209.
- Shimizu, Y. K., Igarashi, H., Kiyohara, T., Shapiro, M., Wong, D. C., Purcell, R. H. & Yoshikura, H. (1998). Infection of a chimpanzee with hepatitis C virus grown in cell culture. *Journal of General Virology* **79**, 1383–1386.
- Shimoike, T., Mimori, S., Tani, H., Matsuura, Y. & Miyamura, T. (1999). Interaction of hepatitis C virus core protein with viral sense RNA and suppression of its translation. *Journal of Virology* **73**, 9718–9725.
- Simmonds, P., Holmes, E. C., Cha, T.-A., Chan, S.-W., McOmish, F., Irvine, B., Beall, E., Yap, P. L., Kolberg, J. & Urdea, M. S. (1993). Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. *Journal of General Virology* **74**, 2391–2399.
- Steinkühler, C., Tomei, L. & De Francesco, R. (1996). In vitro activity of hepatitis C virus protease NS3 purified from recombinant baculovirus-infected Sf9 cells. *Journal of Biological Chemistry* **271**, 6367–6373.
- Stempniak, M., Hostomska, Z., Nodes, B. R. & Hostomsky, Z. (1997). The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme. *Journal of Virology* **71**, 2881–2886.
- Sugawara, Y., Makuuchi, M., Kato, N., Shimotohno, K. & Takada, K. (1999). Enhancement of hepatitis C virus replication by Epstein-Barr virus-encoded nuclear antigen 1. *EMBO Journal* **18**, 5755–5760.
- Sugiyama, K., Kato, N., Mizutani, T., Ikeda, M., Tanaka, T. & Shimotohno, K. (1997). Genetic analysis of the hepatitis C virus (HCV) genome from HCV-infected human T cells. *Journal of General Virology* **78**, 329–336.
- Suzich, J. A., Tamura, J. K., Palmer, H. F., Warrenner, P., Grakoui, A., Rice, C. M., Feinstone, S. M. & Collett, M. S. (1993). Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes. *Journal of Virology* **67**, 6152–6158.
- Tagawa, M., Kato, N., Yokosuka, O., Ishikawa, T., Ohto, M. & Omata,



- M. (1995).** Infection of human hepatocyte cell lines with hepatitis C virus in vitro. *Journal of Gastroenterology and Hepatology* **10**, 523–527.
- Tai, C. L., Chi, W. K., Chen, D. S. & Hwang, L. H. (1996).** The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). *Journal of Virology* **70**, 8477–8484.
- Tanaka, T., Kato, N., Cho, M. J. & Shimotohno, K. (1995).** A novel sequence found at the 3' terminus of hepatitis C virus genome. *Biochemical and Biophysical Research Communications* **215**, 744–749.
- Tanaka, T., Kato, N., Cho, M. J., Sugiyama, K. & Shimotohno, K. (1996).** Structure of the 3' terminus of the hepatitis C virus genome. *Journal of Virology* **70**, 3307–3312.
- Tanji, Y., Hijikata, M., Hirowatari, Y. & Shimotohno, K. (1994).** Hepatitis C virus polyprotein processing: kinetics and mutagenic analysis of serine proteinase-dependent cleavage. *Journal of Virology* **68**, 8418–8422.
- Tanji, Y., Hijikata, M., Satoh, S., Kaneko, T. & Shimotohno, K. (1995a).** Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. *Journal of Virology* **69**, 1575–1581.
- Tanji, Y., Kaneko, T., Satoh, S. & Shimotohno, K. (1995b).** Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. *Journal of Virology* **69**, 3980–3986.
- Taylor, D. R., Shi, S. T., Romano, P. R., Barber, G. N. & Lai, M. C. (1999).** Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. *Science* **285**, 107–110.
- Thomssen, R., Bonk, S., Propfe, C., Heermann, K. H., Köchel, H. G. & Uy, A. (1992).** Association of hepatitis C virus in human sera with beta-lipoprotein. *Medical Microbiology and Immunology* **181**, 293–300.
- Tomei, L., Failla, C., Santolini, E., De Francesco, R. & La Monica, N. (1993).** NS3 is a serine protease required for processing of hepatitis C virus polyprotein. *Journal of Virology* **67**, 4017–4026.
- Tomei, L., Failla, C., Vitale, R. L., Bianchi, E. & De Francesco, R. (1996).** A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activation of the NS3 protease. *Journal of General Virology* **77**, 1065–1070.
- Tsuchihara, K., Tanaka, T., Hijikata, M., Kuge, S., Toyoda, H., Nomoto, A., Yamamoto, N. & Shimotohno, K. (1997).** Specific interaction of polypyrimidine tract-binding protein with the extreme 3'-terminal structure of the hepatitis C virus genome, the 3'X. *Journal of Virology* **71**, 6720–6726.
- Tsukiyama-Kohara, K., Iizuka, N., Kohara, M. & Nomoto, A. (1992).** Internal ribosome entry site within hepatitis C virus RNA. *Journal of Virology* **66**, 1476–1483.
- Valli, M. B., Bertolini, L., Iacovacci, S., Ponzetto, A. & Carloni, G. (1995).** Detection of a 5' UTR variation in the HCV genome after a long-term in vitro infection. *Research in Virology* **146**, 285–288.
- Walter, E., Keist, R., Niederost, B., Pult, I. & Blum, H. E. (1996).** Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. *Hepatology* **24**, 1–5.
- Wang, C., Sarnow, P. & Siddiqui, A. (1993).** Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. *Journal of Virology* **67**, 3338–3344.
- Westaway, E. G., Mackenzie, J. M., Kenney, M. T., Jones, M. K. & Khromykh, A. A. (1997).** Ultrastructure of Kunjin virus-infected cells: colocalization of NS1 and NS3 with double-stranded RNA, and of NS2B with NS3, in virus-induced membrane structures. *Journal of Virology* **71**, 6650–6661.
- Wölk, B., Sansonno, D., Kräusslich, H. G., Dammacco, F., Rice, C. M., Blum, H. E. & Moradpour, D. (2000).** Subcellular localization, stability and trans-cleavage competence of the hepatitis C virus NS3–NS4A complex expressed in tetracyclin-regulated cell lines. *Journal of Virology* **74**, 2293–2304.
- Wu, Z., Yao, N., Le, H. V. & Weber, P. C. (1998).** Mechanism of autoproteolysis at the NS2–NS3 junction of the hepatitis C virus polyprotein. *Trends in Biochemical Sciences* **23**, 92–94.
- Xie, Z. C., Riezu, J. I., Lasarte, J. J., Guillen, J., Su, J. H., Civeira, M. P. & Prieto, J. (1998).** Transmission of hepatitis C virus infection to tree shrews. *Virology* **244**, 513–520.
- Yamada, N., Tanihara, K., Takada, A., Yorihozi, T., Tsutsumi, M., Shimomura, H., Tsuji, T. & Date, T. (1996).** Genetic organization and diversity of the 3' noncoding region of the hepatitis C virus genome. *Virology* **223**, 255–261.
- Yamashita, T., Kaneko, S., Shiota, Y., Qin, W., Nomura, T., Kobayashi, K. & Murakami, S. (1998).** RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. *Journal of Biological Chemistry* **273**, 15479–15486.
- Yan, R. Q., Su, J. J., Huang, D. R., Gan, Y. C., Yang, C. & Huang, G. H. (1996).** Human hepatitis B virus and hepatocellular carcinoma. I. Experimental infection of tree shrews with hepatitis B virus. *Journal of Cancer Research and Clinical Oncology* **122**, 283–288.
- Yan, Y. W., Li, Y., Munshi, S., Sardana, V., Cole, J. L., Sardana, M., Steinkühler, C., Tomei, L., De Francesco, R., Kuo, L. C. & Chen, Z. G. (1998).** Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 angstrom resolution structure in a hexagonal crystal form. *Protein Science* **7**, 837–847.
- Yanagi, M., Purcell, R. H., Emerson, S. U. & Bukh, J. (1997).** Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. *Proceedings of the National Academy of Sciences, USA* **94**, 8738–8743.
- Yanagi, M., St Claire, M., Shapiro, M., Emerson, S. U., Purcell, R. H. & Bukh, J. (1998).** Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. *Virology* **244**, 161–172.
- Yanagi, M., St Claire, M., Emerson, S. U., Purcell, R. H. & Bukh, J. (1999).** In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. *Proceedings of the National Academy of Sciences, USA* **96**, 2291–2295.
- Yao, N., Hesson, T., Cable, M., Hong, Z., Kwong, A. D., Le, H. V. & Weber, P. C. (1997).** Structure of the hepatitis C virus RNA helicase domain. *Nature Structural Biology* **4**, 463–467.
- Yao, N. H., Reichert, P., Taremi, S. S., Prosise, W. W. & Weber, P. C. (1999).** Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. *Structure with Folding and Design* **7**, 1353–1363.
- Yasui, K., Wakita, T., Tsukiyama, K. K., Funahashi, S. I., Ichikawa, M., Kajita, T., Moradpour, D., Wands, J. R. & Kohara, M. (1998).** The native form and maturation process of hepatitis C virus core protein. *Journal of Virology* **72**, 6048–6055.
- Yen, J. H., Chang, S. C., Hu, C. R., Chu, S. C., Lin, S. S., Hsieh, Y. S. & Chang, M. F. (1995).** Cellular proteins specifically bind to the 5'-noncoding region of hepatitis C virus RNA. *Virology* **208**, 723–732.
- Yoo, B. J., Spaete, R. R., Geballe, A. P., Selby, M., Houghton, M. & Han, J. H. (1992).** 5' end-dependent translation initiation of hepatitis C viral RNA and the presence of putative positive and negative translational control elements within the 5' untranslated region. *Virology* **191**, 889–899.
- Yoo, B. J., Selby, M. J., Choe, J., Suh, B. S., Choi, S. H., Joh, J. S., Nuovo, G. J., Lee, H. S., Houghton, M. & Han, J. H. (1995).** Transfection of a differentiated human hepatoma cell line (Huh7) with in vitro-transcribed hepatitis C virus (HCV) RNA and establishment of a long-

term culture persistently infected with HCV. *Journal of Virology* **69**, 32–38.

**Yuan, Z. H., Kumar, U., Thomas, H. C., Wen, Y. M. & Monjardino, J. (1997).** Expression, purification, and partial characterization of HCV RNA polymerase. *Biochemical and Biophysical Research Communications* **232**, 231–235.

**Zeuzem, S., Schmidt, J. M., Lee, J. H., von Wagner, M., Teuber, G. & Roth, W. K. (1998).** Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. *Hepatology* **28**, 245–252.

**Zhao, W. D., Wimmer, E. & Lahser, F. C. (1999).** Poliovirus/hepatitis C virus (internal ribosomal entry site-core) chimeric viruses: improved growth properties through modification of a proteolytic cleavage site and

requirement for core RNA sequences but not for core-related polypeptides. *Journal of Virology* **73**, 1546–1554.

**Zhong, W., Uss, A. S., Ferrari, E., Lau, J. Y. N. & Hong, Z. (2000).** De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase. *Journal of Virology* **74**, 2017–2022.

**Zibert, A., Schreier, E. & Roggendorf, M. (1995).** Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. *Virology* **208**, 653–661.

**Zignego, A. L., Macchia, D., Monti, M., Thiers, V., Mazzetti, M., Foschi, M., Maggi, E., Romagnani, S., Gentilini, P. & Brechot, C. (1992).** Infection of peripheral mononuclear blood cells by hepatitis C virus. *Journal of Hepatology* **15**, 382–386.